title: Somatostatin for Uveitic Cystoid Macular Edema (CME).
abstract: OBJECTIVE
  To report the favorable response of bilateral recalcitrant uveitic cystoid macular edema (CME) to treatment with a somatostatin analog.
  
  
  METHODS
  Medical ophthalmic history and the results of ophthalmic examinations were recorded. Fluorescein angiography (FA) studies were reviewed.
  
  
  RESULTS
  A 52-year-old white female with intermediate uveitis developed bilateral recalcitrant CME. Treatment with subcutaneous injections of the somatostatin analog octreotide resulted in partial resolution of the CME and improvement of visual acuity.
  
  
  CONCLUSIONS
  Somatostatin may play a role in the treatment of CME secondary to uveitis.
authors.affiliation: Ocular Immunology and Uveitis Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
authors.forename: Thekla
authors.initials: T
authors.lastname: Papadaki
authors.forename: Ioannis
authors.initials: I
authors.lastname: Zacharopoulos
authors.forename: Barbara
authors.initials: B
authors.lastname: Iaccheri
authors.forename: Tito
authors.initials: T
authors.lastname: Fiore
authors.forename: C Stephen
authors.initials: CS
authors.lastname: Foster
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007279:Injections, Subcutaneous; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives*; D015867:Uveitis, Intermediate / Q000150:complications*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013004:Somatostatin; D015282:Octreotide